TARSUS PHARMACEUTICALS, INC. (TARS) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $40.14M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $25.43M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $40.14M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $40.14M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $25.43M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $25.43M |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 264.41M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 40.14M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | Contract with Customer, Liability, Current |
| Deferred revenue due within one year | (m) | Contract with Customer, Liability, Current |
| Deferred revenue due after one year | (m) | Contract with Customer, Liability, Current |
| Reported other obligations due within one year | 25.43M USD | Other Liabilities, Current |
| Reported other noncurrent obligations | 15.89M USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) | Contract with Customer, Liability, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $25.43M
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $16.05M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $40.14M | (m) | $25.43M | (m) | $264.41M | (m) | (m) | (m) | $15.89M | (m) |
| 2026-03-31 | (m) | $24.13M | (m) | $32.50M | (m) | $232.18M | (m) | (m) | (m) | $16.08M | (m) |
| 2025-12-31 | (m) | $16.39M | (m) | $22.18M | (m) | $218.73M | (m) | (m) | (m) | $10.60M | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | $199.48M | (m) | (m) | (m) | $10.15M | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | $162.38M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | $158.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | $152.46M | (m) | (m) | (m) | $0.00 | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | $138.82M | (m) | (m) | (m) | $1.24M | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | $124.60M | (m) | (m) | (m) | $1.45M | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | $74.07M | (m) | (m) | (m) | $1.61M | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | $68.50M | (m) | (m) | (m) | $1.75M | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $54.67M | (m) | (m) | (m) | $1.71M | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $41.20M | (m) | (m) | (m) | $1.83M | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $37.81M | (m) | (m) | (m) | $40.00K | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $34.96M | (m) | $0.00 | (m) | $100.00K | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | $33.84M | (m) | $0.00 | (m) | $209.00K | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | $31.32M | (m) | $0.00 | (m) | $343.00K | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | $32.29M | (m) | $174.00K | (m) | $496.00K | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | $12.18M | (m) | $697.00K | (m) | $699.00K | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | $11.27M | (m) | $1.03M | (m) | $905.00K | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | $10.98M | (m) | $1.50M | (m) | $524.00K | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $10.72M | (m) | (m) | (m) | $604.00K | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | $5.99M | (m) | (m) | (m) | $605.00K | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $6.86M | (m) | (m) | (m) | $711.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $919.00K | (m) | (m) | (m) | $100.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |